These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1869245)

  • 1. Etoposide, 6-thioguanine and idarubicin, an oral combination regimen (ETI) for the induction treatment of acute leukemia.
    Ruutu T; Elonen E
    Hematol Oncol; 1991; 9(2):87-92. PubMed ID: 1869245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Finnish Leukemia Group.
    Ruutu T; Almqvist A; Hallman H; Honkanen T; Järvenpää E; Järventie G; Koistinen P; Koivunen E; Lahtinen R; Lehtinen M
    Leukemia; 1994 Jan; 8(1):11-5. PubMed ID: 8289475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral treatment of acute myeloid leukaemia with etoposide, thioguanine, and idarubicin (ETI) in elderly patients: a prospective randomised comparison with intravenous cytarabine, idarubicin, and thioguanine in the second and third treatment cycle.
    Ruutu T; Koivunen E; Nousiainen T; Pelliniemi TT; Almqvist A; Anttila P; Jantunen E; Koistinen P; Koponen A; Mikkola M; Oksanen K; Pulli T; Remes K; Sarkkinen R; Silvennoinen R; Timonen T; Vanhatalo S; Elonen E;
    Eur J Haematol; 2004 Jan; 72(1):38-44. PubMed ID: 14962261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
    Dinndorf PA; Avramis VI; Wiersma S; Krailo MD; Liu-Mares W; Seibel NL; Sato JK; Mosher RB; Kelleher JF; Reaman GH
    J Clin Oncol; 1997 Aug; 15(8):2780-5. PubMed ID: 9256119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.
    Yalman N; Sarper N; Devecioğlu O; Anak S; Eryilmaz E; Can M; Yenilmez H; Ağaoğlu L; Gedikoğlu G
    Turk J Pediatr; 2000; 42(3):198-204. PubMed ID: 11105617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia].
    Liu Y; Ke XY; Ma J; Shen ZX; Zhang XH; Du X; Zhao YM; Lv JQ; Zhan ZM; Zeng XY; Xu XH; Lu ZS
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):706-8. PubMed ID: 17274381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
    Feldman EJ; Alberts DS; Arlin Z; Ahmed T; Mittelman A; Baskind P; Peng YM; Baier M; Plezia P
    J Clin Oncol; 1993 Oct; 11(10):2002-9. PubMed ID: 8410125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous infusion diaziquone and etoposide: a phase I study in adult patients with acute leukemia.
    Lee EJ; Reck K; Schiffer CA
    Leukemia; 1990 Mar; 4(3):189-92. PubMed ID: 2314118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I trial of carboplatin and etoposide given as continuous infusions to adults with leukemia.
    Lee EJ; Reck K; Carter C; Hodges S; Schiffer CA
    Leukemia; 1993 Oct; 7(10):1500-3. PubMed ID: 8412310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idarubicin in blastic crisis of chronic myelogenous leukemia.
    Lambertenghi-Deliliers G; Annaloro C; Cortellaro M; Pozzoli E; Oriani A; Polli EE
    Haematologica; 1991; 76(5):406-8. PubMed ID: 1806446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The GIMEMA Cooperative Group.
    Carella AM; Carlier P; Pungolino E; Resegotti L; Liso V; Stasi R; Montillo M; Iacopino P; Mirto S; Pagano L
    Leukemia; 1993 Feb; 7(2):196-9. PubMed ID: 8426473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose cytosine arabinoside and etoposide in the treatment of relapsed or refractory adult leukemia.
    Gryn J; Conroy J; Topolsky D; Crilley P; Kahn SB; Bulova S; Weiss J; Brodsky I
    Am J Clin Oncol; 1991 Feb; 14(1):52-4. PubMed ID: 1987740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous infusion etoposide/carboplatin for treatment of refractory acute leukemia.
    Letendre L; Noel P; Tefferi A; Solberg LA; Gastineau DA; Hoagland HC
    Am J Clin Oncol; 1995 Oct; 18(5):382-4. PubMed ID: 7572751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia.
    Schlenk RF; Hartmann F; Hensel M; Jung W; Weber-Nordt R; Gabler A; Haas R; Ho AD; Trümper L; Döhner H
    Leukemia; 2002 Apr; 16(4):581-6. PubMed ID: 11960336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral idarubicin in the treatment of acute myelogenous leukaemia and the blast phase of chronic myeloid leukaemia.
    Malik ST; Tucker J; Rohatiner AZ; Brace W; Lister TA
    Hematol Oncol; 1989; 7(6):423-7. PubMed ID: 2807180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule.
    Damon LE; Johnston LJ; Ries CA; Rugo HS; Case D; Ault K; Linker CA
    Cancer Chemother Pharmacol; 2004 Jun; 53(6):468-74. PubMed ID: 15138711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
    Giles FJ; Faderl S; Thomas DA; Cortes JE; Garcia-Manero G; Douer D; Levine AM; Koller CA; Jeha SS; O'Brien SM; Estey EH; Kantarjian HM
    J Clin Oncol; 2003 Mar; 21(6):1050-6. PubMed ID: 12637470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
    Yavuz S; Paydas S; Disel U; Sahin B
    Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: preliminary report of the Argentine Group for Treatment of Acute Leukemia.
    Sackmann-Muriel F; Fernández-Barbieri MA; Santarelli MT; Matus-Ridley M; Rosso A; Negri-Aranguren P; Cerutti I; Gomel M; Kvicala R
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):34-8. PubMed ID: 8290970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytosine arabinoside, idarubicin and divided dose etoposide for the treatment of acute myeloid leukemia in elderly patients.
    Hartmann F; Jacobs G; Gotto H; Schwamborn J; Pfreundschuh M
    Leuk Lymphoma; 2001 Jul; 42(3):347-55. PubMed ID: 11699399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.